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Abstract 
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence 
(NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical effectiveness and cost-
effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin 
with or without ezetimibe, or in combination with ezetimibe (without statin therapy), in adult patients with primary 
hypercholesterolaemia (which includes mixed dyslipidaemia), for whom statins do not provide optimal control of 
their low-density lipoprotein cholesterol (LDL-C) levels and/or for whom statins are contraindicated or not tolerated. 
The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was 
commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the 
evidence for the clinical effectiveness and cost-effectiveness of the technology, based on the company’s submission 
to NICE. The evidence was derived mainly from four randomised controlled trials comparing evolocumab either 
with ezetimibe or placebo in adults with primary familial or non-familial hypercholesterolaemia, who were either 
able to take statins or who were statin-intolerant. The clinical effectiveness review found that evolocumab is 
efficacious at lowering LDL-C, but that there was uncertainty regarding its impact on cardiovascular disease (CVD) 
outcomes. In response to the ERG’s critique of the submitted health economic model, the company submitted an 
amended model, which also included a Patient Access Scheme (PAS). Based on this, the deterministic ICERs for 
evolocumab against ezetimibe were above £74,000 and £45,000 per QALY gained within the non-familial primary 
and secondary prevention population, respectively, whilst the ICERs within the Heterozygous Familial 
Hypercholesterolaemia (HeFH) population were approximately £23,000 per QALY gained. The final determination 
was that evolocumab would be a clinically and cost-effective use of NHS resource in certain patient subgroups. 
 
 
Key points for decision-makers: 
 Guidance on lipid-lowering therapies emphasises managing cardiovascular disease (CVD) risk rather than 
targeting cholesterol concentrations. 
 Evolocumab is efficacious and safe in reducing low-density-lipoprotein cholesterol (LDL-C) in adults with 
primary familial and non-familial hypercholesterolaemia, but there is uncertainty regarding the impact of 
evolocumab on CVD, apheresis and health-related quality of life: there is little or no direct evidence on 
these key outcomes. 
 Inferences have had to be made regarding the impact of evolocumab on CVD risk reduction, based on the 
evidence for statins and ezetimibe, because of high clinical unmet need and high risk of CVD in patient 
groups with inadequately-controlled LDL-C. 
 The Evidence Review Group had doubts regarding the validity of the company’s model results. In the final 
guidance, the Appraisal Committee agreed that evolocumab would be a clinically and cost-effective use of 
NHS resource in certain patient subgroups. Guidance is to be reviewed when a current, ongoing trial 
reports on the relationship between evolocumab and CVD outcomes. 
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1. INTRODUCTION 
Health technologies must be shown to be clinically effective and to represent a cost-effective use of National Health 
Service (NHS) resources to be recommended for use within the NHS in England and Wales. The National Institute 
for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance 
on promoting good health, and preventing and treating ill health, in priority areas with significant impact. The NICE 
Single Technology Appraisal (STA) process usually covers new technologies soon after they have received UK 
marketing authorisation and is specifically designed for the appraisal of a single health technology within a single 
indication [1]. 
 
Within the STA process, the manufacturer of a technology provides NICE with a written submission, containing 
relevant clinical effectiveness evidence alongside a mathematical model that summarises that company’s estimates 
of the cost-effectiveness of the technology. This submission is reviewed by the Evidence Review Group (ERG), an 
external academic organisation independent of NICE, with advice from clinical specialists, and an ERG report is 
produced. After consideration of the company’s submission (CS), the ERG report, and testimony from experts and 
other stakeholders, the NICE Appraisal Committee (AC) formulates the preliminary guidance, the appraisal 
consultation document (ACD), which indicates the initial decision of the AC regarding the recommendation (or not) 
of the intervention. Stakeholders are then invited to comment on the submitted evidence and the ACD, after which a 
subsequent ACD may be produced or a final appraisal determination (FAD) is issued, which is open to appeal. An 
ACD is not produced when the intervention is recommended without restriction; in such instances, a FAD is 
produced directly. 
 
This paper presents a summary of the ERG report [2] and FAD [3] for the STA of evolocumab for adult patients 
with primary familial and non-familial hypercholesterolaemia (which includes mixed dyslipidaemia), for whom 
statins do not provide optimal control of their low-density lipoprotein cholesterol (LDL-C) levels and/or for whom 
statins are contraindicated or not tolerated. It also covers the subsequent development of the NICE guidance for the 
use of this drug in England. Full details of all relevant appraisal documents can be found on the NICE website [4]. 
 
2. DECISION PROBLEM 
Hypercholesterolaemia, a type of hyperlipidaemia, specifically refers to an excessive total plasma cholesterol 
concentration in the blood of approximately >3mmol/L, especially LDL-C [5]. Primary hypercholesterolaemia can 
be familial or non-familial. The former population is principally composed of the heterozygous familial 
hypercholesterolaemia (HeFH) subgroup, which is most commonly diagnosed in the UK using the Simon Broome 
criteria [6, 7], with diagnosis increasingly confirmed with genetic mutation test [8]. LDL-C levels in people with 
HeFH are typically two to three times higher than normal [9, 10]. The prevalence of HeFH within primary 
hypercholesterolaemia in the UK is traditionally stated as 0.2% [5], but recent surveys suggest that up to one in 
every 300 people are affected worldwide [11]. Non-familial primary hypercholesterolaemia is defined as elevated 
LDL-C produced by a combination of effects caused by a variety of genes allied with nutritional and lifestyle factors 
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[5]. The exact role of genetic inheritance in producing elevated LDL-C levels is unclear [12]. Non-familial 
hypercholesterolaemia is the most common form of primary hypercholesterolaemia in the UK; approximately 70% 
of people with primary hypercholesterolaemia have this non-familial type [5]. “Mixed dyslipidaemia” is a type of 
lipid disorder which is termed in the literature as “combined hyperlipidaemia”, a disorder which is characterised by 
elevated LDL-C and high triglycerides (>1.7 mmol/L) and/or reduced or elevated high-density lipoprotein 
cholesterol (HDL-C). Like primary non-familial hypercholesterolaemia, it is also relatively common; approximately 
10% of people with raised cholesterol in the UK have “mixed dyslipidaemia”[5]. Elevated LDL-C is one of the risk 
factors for cardiovascular disease (CVD) [13]. CVD can have major health and economic implications both for 
people and for health services; it remains the most common cause of mortality in women and the second most 
common cause of mortality in men in England [14].  
 
2.1 Current treatment 
The principal lipid-lowering therapies currently prescribed for hypercholesterolaemia are statins, most commonly 
atorvastatin (dose based on risk of CVD, with a maximum dose of 80mg) and ezetimibe (based on inadequate LDL-
C control by statins or statin intolerance or contraindication) [15, 16]. Recent years have seen consistent increases in 
prescription rates for lipid-lowering therapies in England, with the aim of reducing CVD risk [14].  
 
Evolocumab (Repatha®) is a fully human monoclonal antibody that binds selectively to proprotein convertase 
subtilisin/kexin type 9 (PCSK9), a protein that affects the recycling of LDL-receptors on the surface of liver cells 
and decreases the ability of the liver to clear LDL-C from the blood [17]. By binding to PCSK9, evolocumab 
increases the number of LDL receptors expressed by the liver, thereby reducing serum LDL-C levels. The benefits 
of evolocumab are its ability to reduce the level of serum LDL-C in patients who are unable to control their 
cholesterol despite taking a maximum tolerated dose of statins, or in patients who cannot tolerate or take statins. 
Evolocumab is given as either one dose (140mg) every 2 weeks (Q2W) or three doses (420mg) every month (QM), 
administered by subcutaneous injection via a prefilled pen or syringe. The intervention is designed to be self-
administered by the patient after proper training. Evolocumab is indicated in adults with primary 
hypercholesterolaemia (HeFH and non-familial) or mixed dyslipidaemia, as an adjunct to diet. It is to be used in 
combination, either with a statin or with a statin plus other lipid lowering therapies, in patients unable to reach LDL-
C goals with the maximum tolerated dose of a statin, or it is to be used, either as monotherapy or in combination 
with other lipid-lowering therapies, in patients who are statin-intolerant, or for whom a statin is contraindicated [17]. 
It is also indicated for use in populations with homozygous familial hypercholesterolaemia (HoFH).  
 
The CS in this STA proposed evolocumab as an alternative to ezetimibe monotherapy for people in whom statins are 
contraindicated or are not tolerated, or in combination with statins if optimised statin therapy does not adequately 
control LDL-C levels. Evolocumab is also proposed as a treatment, in combination with ezetimibe, when response to 
monotherapy is considered inadequate. Eligible patients are therefore considered to be those at high-risk of a CVD 
event on account of inadequately-controlled LDL-C levels due either to the inappropriateness of statin therapy or 
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due to the failure of a maximum-tolerated dose of statins. This includes people with HeFH; people with HoFH were 
not covered by this appraisal.  
 
In May 2015, NICE issued a final scope to appraise the clinical effectiveness and cost-effectiveness of evolocumab 
for the treatment of patients with primary familial and non-familial hypercholesterolaemia [4]. The principal 
efficacy outcomes for consideration were plasma lipid and lipoprotein levels, including LDL-C, non-HDL-C, HDL-
C, triglycerides (TG), apolipoprotein B (ApoB) and lipoprotein(a) (Lp(a)). The use of LDL-C as a surrogate for 
CVD is generally accepted for statin therapies and the company provided evidence for the relationship between 
LDL-C reduction and the reduction of CVD events, citing the meta-analyses of the Cholesterol Treatment Trialists’ 
Collaboration (CTTC), which found that a reduction of 1mmol/L might lead to 22% reduced risk of CVD events 
[18-21]. CVD events include myocardial infarction (MI) and unstable angina (collectively referred to as Coronary 
Heart Disease [CHD]), stroke, transient ischaemic attack (TIA) and peripheral artery disease (PAD) [22]. However, 
the optimal LDL-C level required to minimise CVD risk is not known. The principal safety outcomes were all also 
considered and reported in the CS: nasopharyngitis, upper respiratory tract infection, headache and back pain. The 
company submitted a de novo health economic model which assessed the cost-effectiveness of evolocumab in terms 
of the incremental cost per quality-adjusted life-year (QALY) gained [4]. 
 
3. INDEPENDENT EVIDENCE REVIEW GROUP (ERG) REPORT 
The ERG report comprised a critical review of the clinical and cost-effectiveness evidence presented in the CS, and 
assessed the appropriateness of the company’s analysis and interpretation of the evidence. In accordance with the 
STA process, the ERG had the opportunity to seek clarification on specific points in the CS, which resulted in the 
company providing additional information [1]. 
 
3.1 Clinical evidence submitted by the company 
The clinical evidence submitted by the company consisted of: (i) a review of the clinical efficacy evidence from 
randomised controlled trials (RCTs) of evolocumab; (ii) a review of the evidence from non-randomised and non-
controlled studies, and; (iii) a review of safety evidence from randomised and non-randomised studies. The principal 
clinical efficacy review included four relevant RCTs. Two trials compared evolocumab with ezetimibe in adults 
with primary non-familial hypercholesterolaemia, who were either able to take statins (LAPLACE-2) [23] or who 
were statin-intolerant (GAUSS-2) [24]. The other two trials were placebo-controlled: one was undertaken in adults 
with primary non-familial hypercholesterolaemia (DESCARTES) [25] and one trial was undertaken in adults with 
HeFH (RUTHERFORD-2) [26]. Three RCTs evaluated both licensed doses of evolocumab (Q2W and QM) and one 
trial (DESCARTES) evaluated only the QM dose. All RCTs were found to be at low risk of bias by the company 
and ERG following quality assessment using the Cochrane risk of bias tool. The following results were presented for 
the primary efficacy outcome of LDL-C: mean percentage change from baseline, and mean percentage treatment 
difference, for a range of follow-up durations. Both of these values were reported for follow-up at 10 and 12 weeks; 
for 12 weeks alone (LAPLACE-2, GAUSS-2, RUTHERFORD-2); and for 12 and 52 weeks (DESCARTES). 
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Detailed results were presented for all trial arms (based on the two licensed evolocumab doses and different 
background statin and comparator treatments).  
 
In the LAPLACE-2 trial, at 12 weeks, patients with primary hypercholesterolaemia on background atorvastatin 
therapy (intensive and non-intensive doses) had a treatment difference in mean percentage change in LDL-C from 
baseline, compared with ezetimibe (fixed effects model), of -46.9 (95% confidence interval [CI], -53.0 to -40.7, 
p<0.001) and -42.5 (95% CI, -47.9 to -37.0, p<0.001), respectively, for the Q2W and QM doses of evolocumab. In 
the GAUSS-2 trial, at 12 weeks, patients with primary hypercholesterolaemia who were statin intolerant had a 
treatment difference in mean percentage change in LDL-C from baseline, compared with ezetimibe, of -39.3 (95% 
CI, -45.0 to -33.5, p<0.001) and -38.1 (95% CI, -42.9 to -33.4, p<0.001) for the Q2W and QM doses of evolocumab.  
 
In the placebo-controlled RUTHERFORD-2 trial, at 12 weeks, patients with HeFH on background statin therapy 
(intensive and non-intensive doses) had a treatment difference in mean percentage change compared with placebo of 
-60.6 (95% CI, -66.7 to -54.5, p<0.001) and -60.3 (95% CI, -67.8, -52.9, p<0.001), respectively, for the Q2W and 
QM doses of evolocumab. The ERG received clinical advice that the proportion of the HeFH population in the 
RUTHERFORD-2 trial with a confirmed genetic mutation was higher than might be found in usual clinical practice 
in the UK, but the implications of this are unclear. Clinical advisors to the ERG also noted that the proportion of 
patients with CHD was higher in the intervention arms of the RUTHERFORD-2 trial (i.e. 30-36%) than would be 
expected in clinical practice in an HeFH population, and was also higher than the prevalence reported for the other 
three trials (e.g. LAPLACE-2 trial arm populations ranged from 17% to 24% with CHD characteristics). In the 
placebo-controlled DESCARTES trial, patients with primary hypercholesterolaemia on background statin therapy 
(intensive and non-intensive doses) had a treatment difference in mean percentage change compared with placebo of 
-59.3 (95% CI, -63.8 to -54.9, p<0.001) at 52 weeks. 
 
Detailed results were also provided in the main submission and appendices for other lipid parameters, as well as pre-
specified and post hoc subgroup analyses based on key covariates. The CS reported that evolocumab provided 
consistent and intensive reductions in LDL-C compared with ezetimibe and placebo, regardless of patient 
population, dosing regimen, CVD risk, and presence or type of background lipid-lowering therapy. The results 
presented within the CS were based on the full analysis set (FAS) of the trials rather than the data reported in the 
original publications. The CS also provided additional efficacy evidence from two open-label extension (OLE) 
studies, which included some slightly different populations in terms of baseline LDL-C and ethnicity (OSLER 1 and 
2) [27], and a single non-RCT (TAUSSIG) undertaken within the HeFH subgroup [28]. The reported findings from 
these studies were consistent with the four key RCTs in terms of LDL-C reduction. 
 
The review of the safety evidence included the four key RCTs, the supplementary studies from the efficacy review, 
and an integrated analysis set, which included a total of 14 RCTs. The CS included extensive safety data on all 
adverse events (AEs), serious adverse events (SAEs), events leading to discontinuation, fatal and common AEs, as 
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well as all-cause mortality and adjudicated CVD events and non-coronary revascularisations, where such evidence 
was available. The CS concluded that the AEs were overall balanced between groups in all three periods of the 
integrated safety data set (12 weeks, 1 year and 2 years), as well as across populations and therapeutic settings, and 
that most AEs were mild to moderate in severity. It also concluded that SAEs and AEs leading to discontinuation of 
the intervention were infrequently reported and generally similar across treatment groups. A number of relevant 
ongoing trials were also listed: OSLER 1 and 2 [27], FOURIER [29] and EBBINGHAUS [30]. 
 
3.1.1 Critique and interpretation of the clinical evidence 
The principal efficacy review represented a good quality systematic review which identified four relevant, good 
quality RCTs. The trials were generally consistent with the final NICE scope. The results for LDL-C and other lipid 
parameters, such as non-HDL-cholesterol, were consistent, and pre-specified subgroup analyses demonstrated that 
these results were not sensitive to the different doses of evolocumab, or other key variables such as LDL-C baseline 
levels, severity of hypercholesterolaemia or CVD risk factors. The ERG noted that only 12-week evidence was 
available for the efficacy of the Q2W dose, whilst the QM dose had some data for 52 weeks. Additional clinical 
efficacy evidence was provided from a non-RCT study (TAUSSIG) and two open-label, extension studies (OSLER 
1 and 2). However, some participants in the extension studies were recruited from trials with populations and/or 
comparators that were excluded from the principal review of the four RCTs and it is unclear how these trials and the 
non-RCT study were identified for inclusion in the company’s review. The inclusion of these studies was justified 
by the company on account of their longer-term evidence. The included efficacy RCTs also excluded potentially 
relevant patients, such as those with diabetes. A network meta-analysis (NMA) was not performed, although it was 
concluded by the ERG it may have been useful in order to quantify the uncertainty associated with the treatment 
effects, as required for subsequent health economic analyses. 
 
The submission of safety evidence was a non-systematic review of good quality RCTs, providing evidence for up to 
two years. There were no obvious safety concerns, with most AEs being balanced across evolocumab and 
comparator trial arms, and very small numbers of SAEs. However, the ERG noted that relatively higher 12-week AE 
rates were reported in patients who had HeFH and statin-intolerant patients who had primary non-familial 
hypercholesterolaemia. Similarly, AE rates were also relatively higher for trials with a longer follow-up duration. 
This suggests that some patient subgroups might experience more frequent events and that all patients are at 
increased risk of AEs over time, although the rates are generally similar to comparators. The ERG noted also that the 
longer-term evidence presented was derived from some trials with populations who would not be eligible to receive 
evolocumab in clinical practice in the NHS (e.g. people who were not on maximum-tolerated doses of statins). 
Further long-term data were therefore needed in relevant UK populations, although it was unclear whether ongoing 
trials would address this. 
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3.2 Cost-effectiveness evidence provided by the company 
The company submitted a model-based health economic analysis as part of their submission to NICE. Following the 
identification of programming errors and inconsistencies by the ERG, revised versions of the model were submitted 
by the company during the clarification process and, again, following submission of the ERG report. The analysis 
was undertaken from the perspective of the NHS over a lifetime horizon. Costs and health outcomes were 
discounted at a rate of 3.5% per annum. The company’s analysis was presented for three populations: (i) patients 
with non-familial primary hypercholesterolaemia who have no history of CVD (primary prevention); (ii) patients 
with non-familial primary hypercholesterolaemia who have existing CVD (secondary prevention), and; (iii) patients 
with HeFH, comprising a mix of patients with no history of CVD and patients with existing CVD (primary and 
secondary prevention). For all three populations, separate analyses were presented for patients who are able to take 
statins (hereafter denoted “ST” - statin tolerant) and for patients for whom statins are contraindicated or not tolerated 
(hereafter denoted “SI” – statin intolerant). The company’s base case analysis assessed evolocumab with/without 
statins. Within all three analyses, modelled comparators included ezetimibe (both with and without statins). 
Additional scenario analyses were presented in which evolocumab was assumed to be used in combination with 
ezetimibe. 
 
The company’s base case model adopted a Markov approach, using an annual cycle length and comprised 24 
mutually exclusive health states: three individual “acute” event states (acute coronary syndrome [ACS], ischaemic 
stroke [IS], heart failure [HF]), where patients remain for a maximum duration of one year unless they experience 
the same event during the next cycle); five individual “chronic” event states (including three “post-event” health 
states - post-ACS, post-IS and post-HF, as well as no CVD and “established” CVD (ECVD); thirteen composite 
CVD health states (including “acute” and “post-event” health states, which contain either two or three individual 
health states); and three death states (CHD death, stroke death and death due to other causes).  
 
Baseline characteristics for the non-familial primary prevention and secondary prevention populations were based 
on the subset of patients in the LAPLACE-2 trial who had LDL-C>2.5mmol/L [23]. Baseline characteristics for the 
HeFH population were based on the modified intention-to-treat (ITT) population of the RUTHERFORD-2 trial [26]. 
The model used risk equations from the Framingham Heart Study [31] and REduction of Atherothrombosis for 
Continued Health (REACH) Registry [32] to predict CVD risk (prior to evolocumab or ezetimibe) and then adjusted 
these using “calibration factors” derived from an analysis of data from the Clinical Practice Research Datalink 
(CPRD) and Hospital Episode Statistics (HES) for the non-familial population[33], or using a calibration factor from 
Benn et al [34] for the HeFH population.  
 
LDL-C reduction is used as a surrogate for a reduction in CVD events. The relationship between LDL-C reduction 
and CVD event reduction was taken from the CTTC meta-analysis [18]. For the ST population, LDL-C treatment 
effects were based on the LAPLACE-2 trial [23]. For the SI population, treatment effects were based on the 
GAUSS-2 trial [24]. Health utilities were based on Euroqol-5D (EQ-5D) and time trade-off (TTO) studies used in 
  
9 
 
the NICE Clinical Guideline(CG) 181 model[15]. The model included the costs of lipid-lowering therapy, 
administration training costs (evolocumab only), monitoring costs, costs of revascularisation procedures, health state 
costs and the costs of CV-related death. Costs associated with managing AEs were not included in the company’s 
model. All costs were valued at 2013/14 prices. Unit costs were taken from the NHS Drugs Tariff, NHS Reference 
Costs [35], the Personal Social Services Research Unit (PSSRU) [36] and a CPRD/HES costing analysis undertaken 
by the company [33]. 
 
The CS contained a large range of analyses, including cost-effectiveness analyses within whole cohorts of patients 
and threshold analyses to determine the 10-year CVD risk at which the incremental cost-effectiveness ratio (ICER) 
for evolocumab would be below £20,000 or £30,000 per QALY gained. Based on the list price analyses, the 
probabilistic ICERs for evolocumab versus ezetimibe were considerably higher than £30,000 per QALY gained 
within the non-familial population and the HeFH population. In response to the critique presented in the ERG report, 
the company submitted a further amended health economic model which addressed some of the ERG’s concerns 
regarding the company’s original model and included a Patient Access Scheme (PAS) for evolocumab based on a 
confidential simple price discount. Based on the company’s amended model and including the PAS, the 
deterministic ICERs for evolocumab against ezetimibe were above £74,000 and £45,000 per QALY gained within 
the non-familial primary and secondary prevention population, respectively, whilst the ICERs within the HeFH 
population were approximately £23,000 per QALY gained. 
 
3.2.1 Critique and interpretation of the cost-effectiveness evidence 
The ERG critically appraised the company’s health economic analyses and the models upon which these analyses 
were based. The ERG identified a number of programming errors and inconsistencies, some of which were rectified 
by the company following the clarification process and following the submission of the ERG report. The ERG’s 
main concerns related to four sets of issues: (a) the conceptual representation of the condition; (b) model process and 
logic; (c) model implementation and mis-specification of evidence inputs, and; (d) uncertainties regarding the 
relationship between LDL-C reduction and CVD events. The ERG also noted further concerns relating to the 
derivation of certain input parameters, the reporting of results, health state utilities and costs. Owing to the 
limitations in the company’s model, the ERG had doubts regarding the validity of the results presented within the 
CS and advised considerable caution in their interpretation and use in informing decision-making.  
 
(a) Conceptual representation of the condition 
Health states within the company’s model are defined by CVD events; this is appropriate for modelling cholesterol-
lowering therapies. However, the choice of which health states (CVD events) should be included in the model is a 
matter of debate. In particular, the ERG noted that the health states used in the company’s model are different from 
those used in the NICE CG181 model [15]. The CS did not include a description of how the health states were 
selected nor did it explain why these should be considered more relevant than those states included in NICE CG181 
[15] or other published models. In particular, the company’s model had the following features: (a) the inclusion of 
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HF as a health state; (b) the inclusion of IS but not haemorrhagic stroke, and; (c) the use of composite health states 
which include a combination of up to three individual health states (e.g. ACS plus post-IS plus post-HF). The ERG 
noted the lack of evidence for the impact of cholesterol-lowering therapies on HF. Furthermore, the company did not 
provide any justification regarding the inclusion of only IS. Whilst it is plausible that people may experience 
multiple different types of CVD events over their lifetime, there are no data available to inform these transitions and 
therefore the company’s model makes a number of arbitrary assumptions regarding maximum event risk in order to 
populate these cells in the transition matrix. 
 
(b) Model process and logic 
For the analysis of patients with non-familial primary hypercholesterolaemia, the company’s model uses a three-step 
approach to estimate the risk of CVD events. This involves: (i) using the Framingham [31] and the REACH Registry 
[32] equations to predict the baseline risk of CVD events depending on individual characteristics in a subset of the 
LAPLACE-2 trial [23]; (ii) estimating calibration factors to adjust predictions from the Framingham [31] and 
REACH [32] equations to “real world data” estimated from the company’s analysis of CPRD/HES data [33], and; 
(iii) adjusting the baseline risks estimated using the Framingham and REACH Registry equations by these estimated 
calibration factors. The ERG considered the company’s approach to be circular, overly-complicated and counter-
intuitive, as it required a number of assumptions and adjustments (such as removing the effect of age and sex) when 
estimating and applying the calibration factors. The ERG considered that it would have been more appropriate to 
estimate baseline CVD risk from the CPRD/HES data directly and to adjust these subsequently using relative risks 
from the published literature to reflect additional risk factors for subgroups, where appropriate. 
 
(c) Model implementation and misspecification of evidence inputs 
The ERG identified several inconsistencies and errors in the implementation of the company’s model. First, the 
company’s model incorrectly treated the predictions from the Framingham [31] and REACH Registry [32] risk 
equations as event rates rather than probabilities. Second, the model misinterpreted what the REACH Registry risk 
equations are predicting [32]; the model incorrectly treated predictions from the REACH Registry risk equations for 
“next CVD event” and “CVD death” as being independent of one another and incorrectly assumed that the risk for 
“next CVD event” predicted by the REACH Registry equation included only non-fatal events. Taken together with 
the absence of constraints, this led to mathematical inconsistencies when the risk of fatal and non-fatal CVD events 
was high. In addition, the ERG also noted a mismatch in evidence whereby the treatment effect used in the model 
did not match the baseline LDL-C level of the population from which it is estimated. With respect to the HeFH 
population, the company estimated the risk of CVD events using the Framingham [31] and REACH Registry [32] 
risk equations in the RUTHERFORD-2 trial and then adjusted these using a rate ratio estimated from Benn et al 
[34], calculated between the general population and patients with HeFH. The ERG considered this to be 
inappropriate as the baseline risk in the non-familial population used in the company’s model already reflects people 
who are at a higher risk due to higher baseline cholesterol. 
 
  
11 
 
(d) Uncertainty regarding the relationship between LDL-C reduction and reductions in CVD events  
The company’s model applied a relationship between LDL-C reduction and reduction in CVD events, quantified in 
terms of the proportional reduction in specific CVD events per mmol/L reduction in LDL-C, based on the CTTC 
meta-analysis [18]. Owing to the lack of data, the model included a number of debatable assumptions and 
simplifications. Notably, the relationship estimated by the CTTC related to the first (recurrent) CVD event; it is 
unclear whether the relationship would be maintained for subsequent events. It is also unclear whether the 
relationship estimated from the CTTC meta-analysis in people receiving statins would hold for evolucumab and 
ezetimibe. In addition, the company’s model further assumed that the relationship between LDL-C reduction and 
non-fatal MI would hold for HF (first event). Assumptions were also made for the effect of LDL-C reduction on 
ECVD. The relative reduction in fatal CVD event rate per mmol/L reduction in LDL-C, from the CTTC meta-
analysis, is applied independently of previous events; this is unlikely to be correct as the reduction in fatal CVD 
events is correlated with the reduction in non-fatal events. 
 
3.3 Additional work undertaken by the Evidence Review Group 
Owing to the number of problems identified within the company’s model, the ERG did not consider it appropriate or 
valuable to undertake additional exploratory analyses prior to the first AC meeting.  
 
3.4 Conclusions of the Evidence Review Group Report 
The ERG recognised that the CS included a good-quality systematic review of the efficacy evidence and that the 
four key RCTs were all good quality and at low risk of bias. Results were consistent across trials for both efficacy 
and safety outcomes. The clinical review found that evolocumab was efficacious at lowering LDL-C. It also found 
that evolocumab was safe. However, the safety evidence, though extensive, was derived in part from trial 
populations that did not reflect the patients likely to present in UK clinical practice, and AE rates appeared to be 
higher in some subgroups; the provision of more long-term safety evidence in these populations was therefore a 
recognised requirement. The ERG noted that the longer-term efficacy and safety evidence from the DESCARTES 
placebo-controlled trial (52 weeks rather than 12 weeks) related only to the evolocumab QM dose; there were no 
equivalent data for the Q2W dose. The ERG also noted that there was no evidence on the relative efficacy of 
evolocumab compared with ezetimibe in the familial hypercholesterolaemia subgroup, or for evolocumab in 
combination with ezetimibe compared with placebo in any population, and there was little or no direct trial evidence 
for evolocumab in terms of HRQoL or apheresis. The ERG also noted that, whilst LDL-C is an accepted surrogate 
outcome for CVD for statins, there was little direct evidence for the relationship between evolocumab and CVD 
events (as a safety outcome). This was the rationale behind the ongoing FOURIER trial (clinicaltrials.gov identifier, 
NCT01764633[29]) (Table 1), which aims to evaluate the impact of evolocumab on CVD outcomes, but only in 
people who have already had a CVD event. 
 
Table 1: Relevant ongoing study of evolocumab (FOURIER) 
[INSERT TABLE 1 HERE] 
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Based on the company model, (excluding revisions to scenarios presented by the company after the Appraisal 
Committee meetings), the probabilistic ICERs for evolocumab versus ezetimibe were considerably higher than 
£30,000 per QALY gained within both the non-familial population and the HeFH population prior to the inclusion 
of the PAS. Including the PAS, the deterministic ICERs for evolocumab versus ezetimibe were above £74,000 and 
£45,000 per QALY gained within the non-familial primary and secondary prevention population, respectively, 
whilst the ICERs within the HeFH population were approximately £23,000 per QALY gained. However, the ERG 
had doubts regarding the validity of the results presented by the company and advised caution in their interpretation 
and use in decision-making. As such, the expected cost-effectiveness of evolocumab in the non-familial and HeFH 
populations remains unclear. 
 
4. KEY METHODOLOGICAL ISSUES 
The health economic model submitted by the company was subject to a number of methodological issues, including 
the estimation of the risk of CVD events and the reliance on the use of a surrogate endpoint to predict the effect of 
evolocumab on CVD events. Given the current clinical evidence base, it remains unclear whether evolocumab is 
associated with a benefit in terms of reduced CVD events and specifically whether the same relationship between 
LDL-C and CVD events observed for statins would also hold for evolocumab and ezetimibe. 
 
5. NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) GUIDANCE 
In May 2016, on the basis of the evidence available, including verbal testimony from invited clinical experts and 
patient representatives, the AC produced the following final guidance to the NHS in England (TA335) [3]. 
Evolocumab was recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, 
only if: 
 The dosage is 140 mg every 2 weeks (Q2W) 
 LDL-C concentrations are persistently above the thresholds specified in Table 2 despite maximal tolerated 
lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by 
intolerance, as defined in NICE’s guideline on the identification and management of familial 
hypercholesterolaemia (CG71) [37]. 
 The company provides evolocumab with the discount agreed in the PAS. 
 
Table 2: LDL-C concentrations above which evolocumab is recommended 
[INSERT TABLE 2 HERE] 
 
5.1 Consideration of clinical effectiveness and cost-effectiveness issues included in the Final Appraisal 
Determination (FAD) 
The full list of the issues considered by the AC can be found in the FAD [3]. The key issues are described in the 
following sections. 
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5.1.1 Uncertainties in the clinical evidence  
The committee agreed that the included RCTs were relevant and of good quality, and noted that evolocumab 
effectively reduced LDL-C by 60–70% compared with placebo in patients with HeFH, and around 40% compared 
with ezetimibe in patients who were statin intolerant. It also noted that, despite the omission of potentially relevant 
patients from the trials, such as those with diabetes, the results could be generalised to clinical practice in England. 
However, the committee noted that current guidance on lipid-lowering therapies emphasises managing CVD risk 
rather than targeting cholesterol concentrations, and that the evolocumab RCTs were not powered to measure CVD 
outcomes. The committee considered this to be an important limitation of the evidence base. It therefore concluded 
that the extent to which evolocumab could reduce CVD was still uncertain, particularly with low concentrations of 
LDL-C at baseline (<3.5mmol/L). However, it accepted the potential impact of evolocumab on CVD risk based on 
the evidence for the alternative therapies, statins and ezetimibe [18, 21]. It also took into account clinical advice 
indicating that groups at high risk of CVD, based on inadequately-controlled LDL-C after treatment with statins 
and/or ezetimibe, have few alternative treatment options, and therapies such as apheresis should be avoided if 
possible. Furthermore, in the absence of robust, long-term data, the committee could not ascertain whether the effect 
of evolocumab would be maintained over time at the same level as when therapy was started. Despite these 
uncertainties, the committee concluded that, in clinical practice, evolocumab should therefore be reserved as an add-
on therapy to statins and ezetimibe for people who are at a high risk of CVD.  
 
5.1.2 Uncertainties in the cost-effectiveness evidence  
The committee considered the internal validity of the model to be unclear owing to the absence of evidence to 
populate all the transitions to the health states within the model. In particular, the committee agreed that the 
modelling of composite health states (combination of events) was based on arbitrary assumptions with little 
evidence. The committee agreed that it was more appropriate to model separately people with non-familial 
hypercholesterolaemia who can or cannot tolerate statins. The committee further noted that using risk equations 
could be appropriate if these reliably predicted the risk of CVD events and considered that the use of QRISK2 [40] 
was more appropriate compared with the Framingham risk equations in people with non-familial 
hypercholesterolaemia without a history of CVD. 
 
For the HeFH population, the committee agreed with the ERG’s suggestion that the secondary and primary 
prevention populations should be assessed separately. The committee further recognised that the risk equations used 
by the company were not derived from people with HeFH and considered that using the rate ratio from Benn et al 
[34] was inappropriate and overestimated of the risk of CVD among these people. As a result, the committee was 
doubtful about the validity of the estimated cost-effectiveness of evolocumab for this population. 
 
The committee raised some uncertainties concerning the company’s model in terms of treatment duration and how 
long treatment would last. The committee further noted that only the cost-effectiveness for the 140mg dosage 
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administered every 2 weeks were presented by the company; thus was only able to make a recommendation for this 
dosage.  
 
Overall, the committee considered that the ICERs presented by the company needed to be interpreted with caution 
owing to the limitations of the model. Despite these concerns, the committee considered that the ICERs for the non-
familial population were above those that are normally considered acceptable. The committee noted that the ICERs 
for the HeFH population were within acceptable range but drew attention to a number of inconsistencies in the 
results for this population. For example, the committee noted that the ICERs in people without CVD were lower 
than those for people with CVD, which contrasted with findings in the non-familial hypercholesterolaemia 
population. The committee heard from the ERG that different CVD events were assumed for the two populations 
and that the calibration of CVD events for the non-familial hypercholesterolaemia population was event-specific, 
whereas a single rate ratio from Benn et al [34] was applied to all CVD events for the HeFH population. In light of 
this, the committee expressed doubts about the face validity of the resulting ICERs. 
 
6. CONCLUSION 
The evidence suggests that evolocumab is efficacious and safe in reducing LDL-C concentrations in patients with 
primary familial and non-familial hypercholesterolaemia. However, current guidance emphasises reduction in CVD 
risk as the key outcome and this was not adequately demonstrated by the available evidence for evolocumab. 
Nevertheless, the committee determined that evolocumab was cost-effective for primary non-familial 
hypercholesterolaemia patients at high or very high risk of CVD, based on prior CV events and LDL-C level, and 
for those with HeFH, but only as long as stated, elevated levels of LDL-C were persistent and inadequately-
controlled on other appropriate therapies. However, the inferences to be drawn from the evidence for statins and 
ezetimibe, and the high clinical unmet need and high risk of CVD in these groups, were deemed sufficient reasons 
for a positive recommendation, despite the absence of direct evidence on the relationship between evolocumab and 
CVD risk reduction. However, the FAD stated that the guidance was to be reviewed when the ongoing FOURIER 
trial reported, although this trial only aims to assess the impact of evolocumab on CVD outcomes in people who 
have already had a CVD event.  
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